A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start Date28 Sep 2023

Sponsor / Collaborator

Apellis Pharmaceuticals, Inc.

JPRN-jRCT2041230022 / RecruitingPhase 3IIT

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS - A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Start Date18 Aug 2023

Sponsor / Collaborator-

NCT05776472 / RecruitingNot Applicable

A Single Arm, Multicentre Observational Study to Evaluate Effectiveness of Pegcetacoplan Under Real World Conditions in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

This is a 24-month multicenter, observational study designed to describe the real world effectiveness of pegcetacoplan in patients with PNH. Patients meeting the eligibility criteria will be enrolled in the study at the enrollment visit and followed prospectively for 24 (+/- 3) months. The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective,collecting data on effectiveness, safety, patient- and clinician-reported outcomes and health care resource use.

Start Date26 Jun 2023

Sponsor / Collaborator

Swedish Orphan Biovitrum AB

100 Clinical Results associated with Pegcetacoplan

100 Translational Medicine associated with Pegcetacoplan

100 Patents (Medical) associated with Pegcetacoplan

162

Literatures (Medical) associated with Pegcetacoplan

01 Jan 2025·INDIAN JOURNAL OF OPHTHALMOLOGY

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies

Review

Author: Yan, Audrey ; Hasan, Nasiq ; Chhablani, Jay

The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. Breakthrough drugs such as pegcetacoplan and avacincaptad have been FDA-approved for dry AMD, marking a significant development as there were no treatment options until August 2023. While several antivascular endothelial growth factor (VEGF) inhibitors have been approved for wet AMD, challenges persist with the need for frequent dosing. New treatments such as gene therapy, cell therapy, WNT pathway agonists, complement inhibitors, and anti-VEGF combination drugs are under development to address these issues. These developments are exciting and hold promise for transforming the field of medicine, offering hope for improved outcomes and enhanced patient care in managing AMD.

01 Jan 2025·International ophthalmology clinics

The Safety of Recently Approved Therapeutics in Age-Related Macular Degeneration

Review

Author: Khanani, Ibrahim ; Gahn, Greggory M. ; Khan, Hannah ; Rahimzadeh, Tyler S. ; Vannavong, Jordyn ; Sulahria, Humza ; Khan, Huma ; Khanani, Arshad M. ; Mojumder, Ohidul ; Aziz, Aamir A. ; Khanani, Zoha A. ; Ali, Haaziq

Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F. Hoffman-La Roche, Basel, Switzerland), aflibercept 8 mg (Regeneron Pharmaceuticals, Tarrytown, NY, USA), and a new device in the port delivery system with ranibizumab (Genentech, San Francisco, CA, USA). The first agents FDA-approved for GA secondary to neAMD are pegcetacoplan (Apellis Pharmaceuticals, Waltham, MA, USA) and avacincaptad pegol (Iveric Bio, Parsippany, NJ, USA). Evaluation of safety in both clinical trials and the real-world has been of paramount importance after the approval of these newest agents to understand their effects in real patients. Real-world data, as demonstrated in both registrational studies along with retrospective chart review studies, has shown to be an important factor in the implementation of newer drugs, along with the treatment decisions that physicians choose to make regarding their dosing and follow-up. This review article discusses the safety of the most recently approved FDA as seen in both clinical trials and real-world studies.

01 Dec 2024·DRUGS IN R&D

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Article

Author: Crass, Ryan L ; Langdon, Grant ; Chapel, Sunny ; Adriaens, Sven ; Smith, Brandon

BACKGROUND AND OBJECTIVE:

Paroxysmal nocturnal hemoglobinuria is a rare blood disorder characterized by life-threatening hemolysis and thrombosis. Complement C5 inhibitor therapy improves symptoms and life prognosis; however, it can result in insufficient hemolysis control, with residual intravascular hemolysis and extravascular hemolysis in some patients. Pegcetacoplan, the first complement C3 inhibitor approved for patients with paroxysmal nocturnal hemoglobinuria, targets both intravascular and extravascular hemolysis. This analysis evaluated population pharmacokinetic/pharmacodynamic profiles of pegcetacoplan.

METHODS:

Pooled clinical study data were used to predict pegcetacoplan concentrations and biomarker responses indicative of hemolysis (hemoglobin and lactate dehydrogenase) over time, including the impact of patient characteristics and prior or concurrent complement C5 inhibitor treatment, to support the approved dose of subcutaneous pegcetacoplan 1080 mg twice weekly.

RESULTS:

The population pharmacokinetoc analysis included 284 subjects, and the pharmacokinetic/pharmacodynamic analysis included 165 subjects. Subcutaneous pegcetacoplan 1080 mg twice weekly resulted in rapid serum exposures and robust biomarker response within 4 weeks after treatment initiation. Steady-state serum concentrations demonstrated consistent exposure (median ≥ 600 µg/mL) with minimal peak-to-trough variation. The median effective half-life was 8.6 days in patients with paroxysmal nocturnal hemoglobinuria. Body weight significantly impacted pegcetacoplan exposure, and other covariates impacted hemoglobin (sex and creatinine clearance) or lactate dehydrogenase (prior or concurrent complement C5 inhibitor treatment); however, effects were not clinically meaningful.

CONCLUSIONS:

The approved dose of pegcetacoplan is predicted to produce rapid and sustained exposure and robust hemoglobin and lactate dehydrogenase responses in adult patients with paroxysmal nocturnal hemoglobinuria, with no initial dose adjustments required for any specific patient population.

258

News (Medical) associated with Pegcetacoplan

03 Dec 2024

·www.prnewswire.com

Sobi's strength in haematology to be showcased at ASH 2024

STOCKHOLM, Dec. 3, 2024 /PRNewswire/ -- New data from Sobi® and partners will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA (USA) from the 7th - 10th of December 2024. During the meeting several analyses will be presented on haemophilia A, haemophagocytic lymphohistiocytosis (HLH), myelofibrosis, paroxysmal nocturnal haemoglobinuria (PNH), and immune thrombocytopenia (ITP). "Haemophilia A has a lasting impact on joint health and quality of life. At ASH 2024, three oral presentations will reveal important new data about long-term outcomes with ALTUVOCT® prophylaxis," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi. "We will also present new data spanning different severe and debilitating rare diseases, including an oral presentation on the real-world effectiveness of Doptelet® in treating people with ITP, demonstrating our broader commitment to advancing innovative treatments for people with rare haematological diseases. We look forward to sharing these findings in San Diego." Key data to be presented at ASH 2024 About ALTUVOCT® ALTUVOCT® (efanesoctocog alfa) [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is the first high-sustained FVIII replacement therapy with the potential to deliver near-normal factor activity levels for a significant part of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. ALTUVOCT builds on the established Fc fusion technology by innovatively adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. The European Commission granted Orphan Drug designation in June 2019. It is approved and marketed as ALTUVOCT by Sobi in Europe. It is approved and marketed as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the United States, Japan, and Taiwan. About the Sanofi and Sobi collaboration Sobi and Sanofi collaborate on the development and commercialisation of Alprolix® and Elocta®/Eloctate®. The companies also collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Gamifant® Gamifant (emapalumab) is an anti-interferon gamma (IFNγ) monoclonal antibody that binds to and neutralises IFNγ. In the USA, Gamifant is indicated for the treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Gamifant is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT). About Vonjo® Vonjo (pacritinib), a JAK-1 sparing JAK2/IRAK1/ACVR1 inhibitor, is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L in the United States. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Currently, a Phase 3 study (PACIFICA) is being conducted to assess pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. About Aspaveli®/ Empaveli® Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as Aspaveli/Empaveli in the United States, European Union, and other countries globally. Currently, a Phase 3 trial (VALIANT) is being conduted to assess the efficacy and safety of pegcetacoplan in patients with C3G and primary IC-MPGN. Aspaveli/Empaveli is also under investigation for several other rare diseases across haematology and nephrology. About the Sobi and Apellis collaboration Sobi and Apellis have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® Doptelet (avatrombopag) is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved in over 30 countries worldwide, including the EU and the US, for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure, and for the treatment of thrombocytopenia in adult patients with primary chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Chronic ITP is a rare autoimmune bleeding disorder characterised by low number of platelets. The incidence of primary ITP in adults is 3.3/100,000 adults per year with a prevalence of 9.5 per 100,000 adults. About Sobi® Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 3ASHOrphan DrugLicense out/in

19 Nov 2024

·endpts.com

FDA rejects Astellas’ effort to support longer use of eye drug Izervay

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data. Izervay, the centerpiece of Astellas’ $5.9 billion acquisition of Iveric Bio , was approved last year to treat geographic atrophy secondary to age-related macular degeneration. The label calls for monthly dosing capped at 12 months, but Astellas had hoped that additional data would support longer use. Astellas announced in April that it submitted two-year data from a Phase 3 trial evaluating safety and efficacy in patients dosed monthly and every other month. But on Tuesday, it said the FDA issued a complete response letter over “a statistical matter related to labeling language proposed by Astellas.” An Astellas spokesperson declined to elaborate further on the rejection, and said the company is “seeking further clarification” from regulators. The company said the FDA’s decision was “unrelated to the safety and benefit/risk” of Izervay. “After discussions with the FDA, Astellas plans to resubmit our application,” the spokesperson said. Izervay competes with Apellis’ Syfovre, which was approved several months before Izervay and has no limitations on treatment duration. However, Apellis’ launch was complicated by rare but serious retinal inflammation concerns. Astellas said on its second-quarter earnings call in October that it estimates 60% of new patients are being placed on Izervay. Astellas has also faced challenges expanding outside of the US. The company pulled Izervay’s marketing application in the European Union last month after regulators expressed concerns about its efficacy. “Although the studies provided by the applicant showed that Izelvay slowed the growth of geographic atrophy lesions, the Agency considered that this effect did not lead to clinically meaningful improvements in visual function for patients,” the European Medicines Agency said. Astellas told Endpoints News Tuesday that it is “exploring potential pathways including resubmission in Europe.”

AcquisitionDrug ApprovalPhase 3Clinical Result

19 Nov 2024

·www.globenewswire.com

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). Key findings include: no drug-related serious adverse events, reduced lesion growth, preservation of retinal tissue, and—most importantly—there was a positive effect on the functional visual measure of low luminance visual acuity (LLVA). Currently, there are approximately three million people living with GA in the United States (U.S.) and Europe combined. Patients in the U.S. have only one option available, anti-complement therapy, which requires multiple injections and only addresses one aspect of the disease. There remains no treatment option for GA in Europe. The OCU410 Phase 1 trial is evaluating nine patients in three dose cohorts (low, medium, and high). The following data was observed for the three patients in the low dose cohort at six months: Considerably slower lesion growth (21.4%) from baseline in treated vs. untreated fellow eyes that followed the natural history of the disease. This result is favorable when compared to published data on pegcetacoplan injected every month or every other month over six months.OCU410 treatment showed increasing preservation of retinal tissue around the GA lesions of treated eyes over six months, which also compared favorably to published data on pegcetacoplan given monthly and every other month.100% of the OCU410 treated eyes showed stabilization of visual function demonstrating treatment benefit as measured by LLVA. “Currently approved treatments for GA have not shown significant benefit in visual function. More importantly, we often do not realize the logistical challenge and emotional burden both patients and their caregivers must endure for every month or every other month visits,” said Syed M. Shah, MD, FACS, Director of Retina Service, Vice Chair for Research & Digital Health at Emplify Health – La Crosse, Wisconsin. “Based on the science and preliminary data, OCU410 has the potential to improve structural as well as functional outcomes. This ‘one-and-done’ treatment paradigm can be a gamechanger for how we treat patients with GA.” “OCU410 addresses multiple aspects of the disease beyond the complement pathway,” said Dr. Huma Qamar, Chief Medical Officer at Ocugen. “The latest OCU410 data emphasizes the potential of novel modifier gene therapy as a one-time treatment for dAMD. We remain very encouraged by the latest safety and efficacy data and positive patient outcomes.” Ocugen also announced promising data from the Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease and data on Leber congenital amaurosis (LCA) from the Phase 1/2 OCU400 clinical trial. All these findings, as well as commentary from study investigators and patient perspectives, were shared at the Company’s recent Clinical Showcase. The data affirms the potential for modifier gene therapy to address both rare inherited retinal diseases and blindness diseases affecting millions. A full replay of the showcase is available on the Events section of the Ocugen website. For more information about Ocugen’s ongoing clinical trials, please contact clinical.request@ocugen.com About Ocugen, Inc.Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs; statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. Contact:Tiffany HamiltonHead of CommunicationsTiffany.Hamilton@ocugen.com

Phase 1Clinical ResultGene Therapy

100 Deals associated with Pegcetacoplan

External Link

KEGG	Wiki	ATC	Drug Bank
D11613	Pegcetacoplan	B03XA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Geographic Atrophy	US	Apellis Pharmaceuticals, Inc.	17 Feb 2023
Hemoglobinuria, Paroxysmal	US	Apellis Pharmaceuticals, Inc.	14 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cold Agglutinin Disease	Phase 3	US	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	JP	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	AT	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	BE	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	CA	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	FI	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	GE	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	DE	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	HU	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	IT	Swedish Orphan Biovitrum AB	20 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03226678 (CTgov)	Phase 2	Cold Agglutinin Disease \| Warm autoimmune hemolytic anemia	24	wAIHA (Part A: Cohort 1 wAIHA - 270 mg)	kzcbiqoyfs(qgojcheyyp) = fmuvucvind qjcyualkxv (yvmjmlyryv, rwhfhbmvwl - cvazyzylhx) View more	-	12 Dec 2024
				wAIHA (Part A: Cohort 1 wAIHA - 360 mg)	kzcbiqoyfs(qgojcheyyp) = mqoaqmovgy qjcyualkxv (yvmjmlyryv, lbewgywvbo - cdfinumpzq) View more
ASH2024	Not Applicable	Hemoglobinuria, Paroxysmal	-	Complement Inhibitor Experienced	wnqulpxlsf(wmidyeutfc) = wsgiwfgibe vllrkiuldx (lwqteidvec, 1.7) View more	-	09 Dec 2024
				Complement Inhibitor Naïve	wnqulpxlsf(wmidyeutfc) = nfrpjfgink vllrkiuldx (lwqteidvec, 1.3) View more
ASH2024	Not Applicable	Hemoglobinuria, Paroxysmal	-	Pegcetacoplan	xpvoegmnpn(uoilnisinj) = 13 patients experienced 1 to 3 acute hemolytic events (n=20, median 1 per patient, IQR [1; 2]) with hospitalization required to manage 6 events xkfkqbmqkb (lantxkgnjx ) View more	-	07 Dec 2024
EURETINA2024	Not Applicable	Geographic Atrophy	-	Pegcetacoplan 15 mg monthly	bqlmndzrku(cgzvstpcnq) = ntqamdlpnb xcslcpwxap (tdzoxoirsc, -1.385 to -0.046)	-	19 Sep 2024
EURETINA2024	Not Applicable	Geographic Atrophy	-	Pegcetacoplan monthly (PM)	unwtpcfbcv(wzyhrudgzu) = the estimated rate of reported events of retinal vasculitis in the post-marketing setting remaining <0.01% per injection with an estimated 215,000 injections administered in the real-world setting through February 2024 omkxyuaezu (xcmlfcmqij )	-	19 Sep 2024
				Pegcetacoplan every other month (PEOM)
EURETINA2024	Not Applicable	Geographic Atrophy	-	Pegcetacoplan 15 mg per 0.1 mL intravitreal injection monthly	ihetnhujcg(hovusvjfcd) = zuycrtkykx yejswfpjsr (wgxxcjkptm, 0.09)	-	19 Sep 2024
				Pegcetacoplan 15 mg per 0.1 mL intravitreal injection every other month	ihetnhujcg(hovusvjfcd) = acmwvfblfg yejswfpjsr (wgxxcjkptm, 0.09)
NCT04085601 \| NCT03531255 \| NCT03500549 (MDS-397, SOHO2024)	Phase 3	Hemoglobinuria, Paroxysmal	133	Pegcetacoplan 1080 mg subcutaneously twice weekly	tcfspfxelt(tamxekagyj) = cwotmlqayg cxtenmillh (aijkkhrwwa ) View more	Positive	04 Sep 2024
				Placebo	dxyjuzbvmu(omsohlhpkh) = omyqwpsumy pzkrxvkpem (dlpriaizzg, 1409.0 - 2503.3) View more
NCT05067127 (VALIANT, GlobeNewswire) Manual	Phase 3	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	124	Pegcetacoplan	rseymgafyn(mucbfucgld) = wygzgiyird mwgtsnikzb (vduucphqtm ) Met View more	Positive	08 Aug 2024
				Placebo	ondwfsfhvm(nstkevbwiv) = ybsiahklgr qlwjxaequb (lcfornnrku )
NCT04085601 \| NCT03500549 \| NCT02588833 (PADDOCK \| PRINCE \| PEGASUS, Pubmed)	Not Applicable	Anemia \| Hemoglobinuria, Paroxysmal	25	Pegcetacoplan	hbhugiadwm(ppadahwvgk) = increased scpbimawyh (idezjliubt ) View more	Positive	29 Jul 2024
				Eculizumab
NCT04770545 (GALE, GlobeNewswire) Manual	Phase 3	Geographic Atrophy	792	SYFOVRE® (pegcetacoplan injection) (monthly)	egafkpuadz(qspaaomruk) = znmztbephp dooqtvlkzz (oqlmwinloy )	Positive	10 Jun 2024
				SYFOVRE® (pegcetacoplan injection) (every-other-month)	-

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis